Alternative splicing for tuneable expression of protein subunits at desired ratios

Christel Aebischer-Gumya Drug Substance Development, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, SwitzerlandView further author information

Pierre Morettia Drug Substance Development, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, SwitzerlandView further author information

Timothee Brunstein Laplacea Drug Substance Development, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, SwitzerlandView further author information

Jana Franka Drug Substance Development, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, SwitzerlandView further author information

Ysaline Granda Drug Substance Development, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, SwitzerlandView further author information

Farid Mosbaouia Drug Substance Development, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, SwitzerlandView further author information

Emilie Hilya Drug Substance Development, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, SwitzerlandView further author information

Anna Galeaa Drug Substance Development, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, SwitzerlandView further author information

Megane Peltreta Drug Substance Development, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, SwitzerlandView further author information

Carole Estoppeyb Antibody Engineering, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, SwitzerlandView further author information

Daniel Ayoubc Analytical Development, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, Switzerland

Roberto Giovanninid Process Sciences, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, SwitzerlandView further author information

Martin Bertschingera Drug Substance Development, Ichnos Sciences SA (formerly Glenmark Pharmaceuticals SA), La Chaux-de-Fonds, SwitzerlandCorrespondence[email protected]
View further author information

Your download is now in progress and you may close this window